A Landmark Announcement
The World Health Organization (WHO) just shook things up: On 5 September 2025, WHO added GLP-1 drugs for obesity and diabetes to its Essential Medicines List (EML), and urged pharmaceutical companies to develop affordable generic versions. Drugs like Ozempic and Mounjaro have officially been added to the Essential Medicines List; a guide usually reserved for lifesaving treatments like antibiotics or HIV medication that countries are urged to prioritize. So what happens when weight-loss injections join that club? Let’s dive in!
Why This Matters Globally
In essence, WHO is declaring that obesity and diabetes deserve the same level of attention as other major health conditions. This is a huge milestone. By putting GLP-1 drugs on the list, WHO is saying: obesity and diabetes deserve the same level of attention as other major health conditions. When the world’s top health body calls a drug “essential,” it signals to governments, insurers, and aid organizations that these medications are not luxury treatments but vital tools in tackling global health challenges.
For years, obesity was brushed off as a lifestyle problem. WHO’s move flips that narrative. By putting GLP-1s on the Essential Medicines List, the organization is saying obesity and diabetes are serious medical conditions that deserves medical solutions and treating these with modern drugs is not optional, it is essential. This decision reframes obesity as a medical condition worthy of serious treatment.
The Good News: What Could Change
WHO’s move could eventually make GLP-1 drugs more visible, affordable, and globally accessible. Key changes that this can bring include:
- Visibility: Obesity treatment gets global recognition, reducing stigma
- Hope for Generics: WHO is urging affordable versions, which could bring prices down
- Global Reach: Countries with rising diabetes rates could gain access if cheaper supplies become available
The Challenges: Symbolism vs. Reality
But let’s be clear, putting a drug on a list doesn’t automatically make it appear on pharmacy shelves. Many “essential” medicines still face shortages. GLP-1 drugs remain among the most expensive treatments today, with demand already outpacing supply. That opens the door to more black-market sales and counterfeit products. Unless affordability and regulation improve, access will remain uneven. What is important to note here is that symbolism doesn’t guarantee availability, cost and supply are still major barriers.
What It Means for Ordinary People
If you’re living with obesity or diabetes, this decision won’t change your access overnight. Insurance, national health systems, and personal finances still matter more in the short term. But it does set the stage for future progress. It validates patient struggles and says: your condition is real, serious, and deserves medical solutions. Right now, we are seeing only little changes day-to-day, but the WHO decision lays the foundation for future access.
The Ripple Effect: Looking Ahead
Historically, when WHO adds a drug to its list, it pressures governments to negotiate better prices, encourages pharma to increase production, and eventually paves the way for generics. Imagine a world where someone in Ghana or India can access these same drugs through public health systems, not because they’re wealthy but because they’re considered essential. That’s the long-term promise of this decision. The real impact may be seen years from now, as the decision pushes prices down and broadens access globally.
Final Thoughts: A Symbolic Win, With Work to Do
This move by WHO is a milestone but not the finish line. It won’t magically make GLP-1 drugs affordable tomorrow, but it changes the conversation. It signals to patients: you matter, your condition matters, and your treatment matters. WHO has opened the door. Now governments, insurers, and pharma must decide how wide it will swing.